Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

2(50%)

Results Posted

400%(4 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Terminated(1)

Detailed Status

Active, not recruiting2

Completed1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

active_not_recruiting250%

completed125%

terminated125%

Recent Activity

2 active trials

Showing 4 of 4

terminatedphase_3

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

NCT02842086

active_not_recruitingphase_3

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

NCT04994509

active_not_recruitingphase_3

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

NCT04925752

completedphase_3

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

NCT03547908

Clinical Trials (4)

Showing 4 of 4 trials

NCT02842086Phase 3

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Terminated

NCT04994509Phase 3

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Active Not Recruiting

NCT04925752Phase 3

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Active Not Recruiting

NCT03547908Phase 3

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4